We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.75% | 13.37 | 13.41 | 13.30 | 13.34 | 1,333,986 | 01:00:00 |
From May 2021 to May 2024
By Stephen Nakrosis
Biopharmaceutical company Calithera Biosciences Inc. on Monday said was expanding its oncology pipeline as it agreed to acquire two clinical-stage compounds from Takeda Pharmaceutical Co. Ltd.
Calithera said the compounds, sapanisertib and mivavotinib, strengthen its pipeline of clinical-stage targeted therapies. Susan Molineaux, the company's president and chief executive, said "We believe that these clinical-stage compounds are an excellent complement to our internally-developed pipeline programs, and fit well with our current strategic focus on biomarker-driven therapeutic approaches."
She also said the company plans to start clinical trials for both compounds and generate data in the next 12 to 18 months.
At 4:18 p.m. ET, Calithera stock had risen 4.48% to $2.10.
The stock finished the day's regular-trading session with a 1.47% loss, closing at $2.01 a share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 18, 2021 16:39 ET (20:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
